Could Start-Up Adagio’s COVID-19 Antibody Have A Fighting Chance?

 
• By Alaric DeArment

The company announced a $336m series C round, six months after it raised an $80m series B, to support development of an easily administered treatment ADG20.

Antibodies immunoglobulins attacking coronavirus covid-19 influenza virus cell, 3D immune system medical illustration background. Corona virus 2019-ncov sars cell, igm. Coronavirus sars-cov-2 disease
Adagio announced that it had raised a $336m series C funding round for its coronavirus therapeutics • Source: Shutterstock

More from COVID-19

More from Scrip